Sentinel node biopsy in T2 breast cancers larger than 3 cm and clinically negative axilla compared with the T1-T2 < 3 cm standard indication;La biopsia del ganglio centinela en cáncer de mama de más de 3 cm y axila clínicamente negativa frente a la indicación estándar T1-T2 < 3 cm

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 3, 2008, Pages 176-182

  Ruano Perez R ^a   Ramos, M ^a   Garcia Talavera J R ^a   Garcia Macias M C ^a   Martin De Arriba A ^a   Gonzalez Orus J M ^a   Iglesias, M ^a   Serrano, E ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Axillary staging; Breast cancer; Sentinel node biopsy; T > 3 cm tumours

Indexed keywords

ISOSULFAN BLUE; RHENIUM SULPHIDE; TECHNETIUM 99M;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; FEMALE; FOLLOW UP; GAMMA RADIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; RELAPSE; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 44949244071     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13121027     Document Type: Article

References (30)

1. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel lymph node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983-90.
2. Intra M, Rotmensz N, Mattar D, Gentilini OD, Vento A, Veronesi P, et al. Unnecessary axillary node dissections in the sentinel lymph node era. Eur J Cancer. 2007;43:2664-8.
3. Cortes M, Bajen MT, Gil M, Benito E, Moreno A, Guma A, et al. Simultaneous location of non-palpable breast neoplasms and sentinel node (SN) study by radioisotopic techniques. Rev Esp Med Nucl. 2005;24:101-6.
4. Ronka R, Krogerus L, Leppanen E, von Smitten K, Leidenius M. Radio-guided occult lesion localization in patients undergoing breast-conserving surgery and sentinel node biopsy. Am J Surg. 2004;187:491-6.
5. Kumar R, Jana S, Heiba SI, Dakhel M, Axelrod D, Siegel B, et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J Nucl Med. 2003;44:7-10.
6. Barros A, Cardoso MA, Sheng PY, Costa PA, Pelizon C. Radioguided localization of non-palpable breast lesions and simultaneous sentinel lymph node mapping. Eur J Nucl Med Mol Imaging. 2002;29:1561-5.
7. Benítez A, Bajen MT, Rodríguez A, Guirao S, Ferrán N, Ricart Y, et al. Lymphoscintigraphy and sentinel node biopsy in non-palpable breast cancer. Rev Esp Med Nucl. 2006;25:250-7.
8. Armas F, Intra M, Vega V, Isla C, Hernández MJ. Radioguided surgery of non-palpable breast lesions. Rev Esp Med Nucl. 2007;26:107-20.
9. Olson JA, Fey J, Winawer J, Borgen PI, Cody HS, Van Zee KJ, et al. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg. 2000;191:593-9.
10. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8:688-92.
11. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88:2540-5.
12. Leidenius MH, Krogerus LA, Toivonen TS, von Smitten KA. Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Eur J Surg Oncol. 2005;3:364-8.
13. Lelievre L, Houvenaeghel G, Buttarelli M, Brenot-Rossi I, Huiart L, Tallet A, et al. Value of the sentinel lymph node procedure in patients with large size breast cancer. Ann Surg Oncol. 2007;14:621-6.
14. Schüle J, Frisell J, Ingvar C, Bergkvist L. Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br J Surg. 2007;94:948-51.
15. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-9.
16. Varghese P, Mostafa A, Abdel-Rahman AT, Akberali S, Gattuso J, Canizales A, et al. Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. Eur J Surg Oncol. 2007;33:147-52.
17. Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 2004;30:913-7.
18. Cserni G, Rajtar M, Boross G, Sinko M, Svebis M, Baltas B. Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer. World J Surg. 2002;26:592-7.
19. Cox CE, Salud C, Whitehead GF, Reintgen DS. Sentinel lymph node biopsy for breast cancer: combined dye-isotope technique. Breast Cancer. 2000;7:389-97.
20. Villa G, Gipponi M, Buffoni F, Vecchio C, Bianchi P, Agnese G, et al. Localization of the sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye and intraoperative gamma probe. Tumori. 2000;86:297-9.
21. Canavese G, Gipponi M, Catturich A, Di Somma C, Vecchio C, Rosato F, et al. Sentinel lymph node mapping in early-stage breast cancer: technical issues and results with vital blue dye mapping and radioguided surgery. J Surg Oncol. 2000;74:61-8.
22. Linehan DC, Hill AD, Akhurst T, Yeung H, Yeh SD, Tran KN, et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol. 1999;6:450-4.
23. Motomura K, Egawa C, Komoike Y, Kataoka T, Nagumo S, Koyama H, et al. Sentinel node biopsy for breast cancer: technical aspects and controversies. Breast Cancer. 2007;14:25-30.
24. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-20.
25. McCready D, Holloway C, Shelley W, Down N, Robinson P, Sinclair S, et al. Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg. 2005;48:185-94.0
26. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;7:546-53.
27. Piñero A, Giménez J, Merck B, Vázquez C. Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease. Rev Esp Med Nucl. 2007;26:176-80.
28. Van der Vegt B, Doting MH, Jager PL, Wesseling J, de Vries J. Axillary recurrence after sentinel lymph node biopsy. Eur J Surg Oncol. 2004;30:715-20.
29. Domènech A, Benítez A, Bajén MT, Pla MJ, Gil M, Martín-Comín J. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years. Oncology. 2007;72:27-32.
30. Bergkvist L, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Frisell J; on behalf of the Swedish Breast Cancer Group; Swedish Society of Breast Surgeons. Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer: Three-Year Follow-Up of the Swedish Multicenter Cohort Study. Ann Surg. 2008;247:150-6.